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Background/aim: The aim of the present study was to examine the anticancer effects of combination treatment with artemisinin and
iron on the human gastric cancer cell line.
Materials and methods: The AGS cell line was cultivated separately as a monolayer in culture flasks and different doses of 99% pure
artemisinin with invariable doses of iron sulfate were added to the culture media and adhesive cells on the flask’s bottom were stained
with hematoxylin–eosin for a pathological assay.
Results: Damage to cancerous cells increased dose dependently and it was higher in the combination treatment groups (artemisinin
plus iron). The histopathological changes were observed specially in the groups with high artemisinin concentration as cell swelling,
nucleus swelling, and formation of small and large vacuolization. Necrotic changes as nucleus pyknosis were seen too. Changes in
groups receiving both artemisinin and iron gradually became more severe with dose increase.
Conclusion: Pathologic studies showed that the cytotoxic effects of artemisinin were dose dependent and the presence of iron enhanced
the artemisinin’s anticancer potency.
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1. Introduction
The anticancer effects of artemisinin and different
combination therapies with it have been shown in many
in vivo and ex vivo experiments such as in leukemia and
breast and prostate cancer (1–8). Artemisinin, a traditional
Chinese medicine, is derived from (the Chinese plant
qinghao) Artemisia annua. Recently it has been widely used
as an antimalarial and anticancer agent. This sesquiterpene
phytolactone compound possesses an endoperoxide
bridge that reacts with free iron and generates organic
free radicals that cause induction peroxidation of the cell
membrane’s lipid (9–11). This process initiates apoptosis
and necrosis of the cell and leads to cell death (7,12,13).
Gastric cancer is a major cause of mortality. Its
prevalence is decreasing in industrial countries, but it
is still the fifth global mortality cause after lung, breast,
colorectal, and prostate cancer and it is third placed after
lung and liver cancer in East Asia. Various kinds of gastric
cancer exist based on the tissue involved. Adenocarcinoma
is one of the most prevalent types of gastric cancer and it
has been involved in 95% of reported mortalities (14,15).
* Correspondence: mahsa.alem@gmail.com
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The AGS cell line, a human gastric adenocarcinoma,
is a suitable model for studying stomach cancer and
evaluating cancer cell apoptosis (14).
The aim of our research was to study the anticancer
effects of combination treatment with artemisinin and
iron on the human gastric cancer cell line.
2. Materials and methods
The AGS (ATCC CRL1739) human stomach
adenocarcinoma epithelial cell line was obtained from
the National Cell Bank of Iran (Pasteur Institute, Iran).
There were Roswell Park Memorial Institute (RPMI 1640)
without antibiotics, with 10% fetal bovine serum (FBS),
and nonessential amino acids in the cell media.
This line was cultivated separately as a monolayer
in T25 culture flasks containing RPMI 1640 medium
supplemented with 10% FBS. The cells were grown in an
incubator at 37 °C with 5% CO2 and 95% humidity. They
were classified into 9 groups. Culture media refreshment
was done every 3 days.
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Different doses of 99% pure artemisinin, with invariable
doses of iron sulfate (10 µg/mL) were added to the culture
media. Nine different groups were classified. Four groups
received one dose of artemisinin (0.15, 0.3, 0.6, and 1.2 µg/
mL) with iron sulfate, and the same doses of artemisinin
were added to another four groups (3) without iron. One
group was considered the iron control (Table).
The cellular alterations were checked and photographed
under an inverted microscope every 12 h. At the end of
the study, adhesive cells on the flask’s bottom were fixed
with methanol and stained with hematoxylin–eosin for a
pathological assay.
There were three culture media for each dose during
this experiment in order to confirm the accuracy of the
histopathological results.
3. Results
Damage to cancerous cells increased dose dependently
and was higher in the combination treatment groups
(artemisinin plus iron). In the histopathological
investigations, the changes observed were as follows. In the
artemisinin groups (without iron) pathological changes
were observed only in two groups with artemisinin
concentration of 0.6 and 1.2 in the form of cell swelling,
formation of small vacuoles in small quantities in cells,
and swelling of the cell nucleus.
Changes in groups receiving both artemisinin and iron
gradually became more severe with dose increase. Some
cells showed mild swelling with a dose of 0.15. In a dose of
0.3, cell and nucleus swelling were seen. In doses of 0.6 and
1.2, severe cell swelling and severe and large vacuolization
of cells were seen. Some cells showed necrotic changes
in the form of nucleus pyknosis. Fragmentation of cell
cytoplasm was also observed. Dislodging of the cells from

the bottom of the culture medium and depletion of the
bottom were minimal in the group of 0.6 but maximal in
the group of 1.2.
These lesions were severely dependent on dose and
time and became more severe over time. However, in the
last investigation at 60 h some new mitosis was observed
at the bottom of the culture medium in compensation for
depleted cells. In the group of 1.2 with iron, in the last
hours necrotic lumps sticking together were observed
(Figures 1–3).
4. Discussion
Because of the metabolic activity of cancerous cells, they
have massive quantities of iron deposits; on the other
hand, artemisinin has selective uptake through transferrin
receptors (related to iron) and these factors lead to the
selective cytotoxicity of artemisinin on neoplastic cells.
However, there is no effect on normal cells (selective
toxicity) (16).
In the present study, the anticancerous effects of
different doses of artemisinin alone and mixed with
ferrous sulfate were studied.
Lai et al. (17) showed that iron and artemisinin cause
formation of free radicals and were highly toxic for
leukemic and breast cancer cells.
Efferth et al. (12) stated that iron and transferrin
increased the cytotoxicity of artemisinin toward leukemia
and astrocytoma cells. This enhancement was 1.5–10.3fold compared with artemisinin alone. In addition,
Shahbazfar et al. (3) found that combination therapy with
artemisinin was more effective than single therapy against
cancerous cells of bladder and breast cancer. Furthermore,
the synergistic effects of iron and artemisinin have been
indicated in other studies.

Table. Drug composition of different doses of artemisinin with invariable dose of iron
sulfate (10 µg/mL) in the treatment groups.
Group

Agents

1

Artemisinin (0.15 µg/mL) + iron sulfate

2

Artemisinin (0.3 µg/mL) + iron sulfate

3

Artemisinin (0.6 µg/mL) + iron sulfate

4

Artemisinin (1.2 µg/mL) + iron sulfate

5

Artemisinin (0.15 µg/mL)

6

Artemisinin (0.3 µg/mL)

7

Artemisinin (0.6 µg/mL)

8

Artemisinin (1.2 µg/mL)

9

Iron control
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Figure 1. (A) Cell swelling and dislodging of the cells from the bottom of the culture medium in group 3 (artemisinin 0.6 µg/mL
+ iron sulfate); invert microscopy; hour 60; AGS cell line ×40; (B): Cell swelling, dislodging of the cells from the bottom of the
culture medium, necrotic lumps sticking together in group 4 (artemisinin 1.2 µg/mL + iron sulfate); invert microscopy; hour 60;
AGS cell line ×40; (C): Cells were steady in group 6 (artemisinin 0.3 µg alone) and did not show any specific pathologic changes;
invert microscopy; hour 60; AGS cell line ×40.

Figure 2. Fine vacuolation in cytoplasm of cells in group 7
(artemisinin 0.6 µg alone); H and E staining; hour 60; AGS cell
line ×1000.
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Figure 3. Several areas of fine vacuolation in the cytoplasm of
cells in group 8 (artemisinin 1.2 µg alone). One necrotic cell with
pyknotic nucleus is shown; H and E staining; hour 60; AGS cell
line ×1000.
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In conclusion, artemisinin has been studied in several
cancer cell lines but there were no data about artemisinin/
iron combination treatment against the AGS cell line
according to our search. The results of our study showed
that the addition of iron enhanced the cytopathic effects of
artemisinin against AGS cancer cell lines.

Pathologic studies showed that the cytotoxic effects of
artemisinin were dose‑dependent and the presence of iron
enhanced artemisinin’s anticancer potency.
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